Zura Bio Limited — Q1 2024 Form 10-Q
Business context and period: Unaudited results for the three months ended March 31, 2024, compared with the same period in 2023. Zura is a clinical-stage biotechnology company developing immunology assets, including ZB-168 (licensed from Pfizer), torudokimab (ZB-880) and tibulizumab (ZB-106, licensed from Lilly). It has no approved products and has generated no product revenue.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 / comparative |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $3.6 million | $4.9 million |
| General and administrative expense | $4.8 million | $2.8 million |
| Total operating expenses / operating loss | $8.4 million / $(8.4) million | $7.7 million / $(7.7) million |
| Interest income | $1.2 million | $0.001 million |
| Net loss | $(7.7) million | $(9.6) million |
| Net loss attributable to Class A shareholders; basic and diluted EPS | $(0.7) million; $(0.02) | $(9.8) million; $(2.76) |
| Cash and cash equivalents at period-end | $89.8 million | $44.0 million at March 31, 2023 |
| Operating cash flow | $(5.0) million | $(3.3) million |
| Investing cash flow | $(5.0) million | $0 |
| Current assets / current liabilities | $90.5 million / $14.7 million | $100.8 million / $20.3 million at December 31, 2023 |
| Total liabilities | $16.3 million | $21.3 million at December 31, 2023 |
No revenue-based gross margin is applicable. The company reported no outstanding note payable or other borrowing at March 31, 2024; liabilities included $1.6 million in private placement warrant liabilities. Accumulated deficit was $111.2 million. Cash declined $10.0 million during the quarter, including a $5.0 million cash payment relating to the 2023 Lilly license.
Material changes versus the prior comparable period
- Operating expenses rose 9% to $8.4 million. R&D expense fell 26%, mainly because Q1 2023 included Pfizer anti-dilution share compensation and a remeasurement expense for Lilly license consideration; the decline was partly offset by higher personnel, consulting and manufacturing costs.
- G&A expense increased 69%, primarily from higher compensation and share-based compensation, alongside increased public-company, travel and office costs.
- Net loss narrowed year over year, in part because Q1 2023 included a $2.2 million fair-value loss on a note that was repaid at the business combination. Q1 2024 included $1.2 million of interest income and a $0.6 million warrant revaluation loss.
- Q1 2024 included a $7.0 million adjustment reducing redeemable noncontrolling interest from redemption value to carrying value. Consequently, the reported loss attributable to Class A shareholders differs substantially from consolidated net loss; per-share comparisons should be interpreted in that context.
Outlook, risks and unusual items
- Management expects operating expenses to increase as it advances development, clinical programs, manufacturing and public-company operations. No specific revenue or earnings guidance was provided.
- Management said that, based on current plans, proceeds from the business combination and private placements should fund operating expenses and capital requirements through at least the next 12 months. This estimate depends on assumptions and could change; further financing may be needed.
- After quarter-end, the April 2024 private placement closed for approximately $112.5 million gross proceeds, before fees and expenses. It included ordinary shares and pre-funded warrants and therefore adds potential dilution. The company also reported that its fully diluted share count had triggered a $5.0 million fee to BAFFX17, which became due April 24, 2024.
- The 2022 Lilly license provides for a $3.0 million payment upon completion of a financing exceeding $100 million. The subsequent April financing exceeded that threshold; investors should verify the resulting obligation and its recognition or payment status. The filing stated that contingent payments were not due as of March 31.
- License agreements include substantial contingent development, regulatory and sales milestones and royalties. Disclosed maximums include Pfizer development/regulatory milestones of $70 million and sales milestones of $525 million; Lilly agreements also carry material milestone and royalty obligations. Timing and ultimate amounts depend on future events.
- Key risks include clinical and regulatory failure, substantial ongoing cash needs, reliance on third-party manufacturers and contractors, and potential supply disruption related to scrutiny of WuXi Biologics and China. The filing also notes that cash balances at financial institutions regularly exceed the $250,000 federally insured limit.
- The CEO transition from founder Someit Sidhu to Robert Lisicki took effect April 8, 2024. Management reported disclosure controls were effective at a reasonable assurance level; no material change in internal control was identified. The company reported no material litigation.
Important facts for investors to verify
- Cash runway assumptions after accounting for the net proceeds and dilution from the April 2024 financing, as well as the $5.0 million BAFFX17 fee and any $3.0 million Lilly payment triggered by that financing.
- Updated share count and potential dilution from the April placement, pre-funded warrants, existing warrants, equity awards and the Z33 put right.
- Clinical-development status and expected milestones for each asset, including the basis for describing programs as advancing toward Phase 2 and the company’s statement that it had not conducted clinical trials itself.
- Expected R&D spending, manufacturing capacity and continuity of supply, particularly for programs dependent on third-party providers.
- Future milestone, royalty and other license obligations, including payment triggers and their potential effect on capital needs.